comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 02:28:07 - browse：12215

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： After John Oliver segment, STAT readers share their opioid

WSS

Kim Kardashian sparks debate on benefits of full

An innovative path out of biotech’s “valley of death”

Pharma budget tightening trickles down to Doximity

Novo acquires Inversago for up to $1 billion

Readout LOUD podcast, live from the STAT Breakthrough Summit East

This gene therapy has record $4.25 million price. It's saved children.

Wikipedia

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Pregnancy ages women, but effects reverse after delivery

Virginia high school admissions case could be legal follow

Steward Health Care expansion into Malta flopped

In Memoriam: Notable people who died in 2023

Bring on the sabbaticals for nurses

Moonlake's readout produced a cash windfall. Risks remain

Pfizer, Moderna say biotech, pharma drug development is a sprint

ChatGPT in medicine: STAT answers readers' burning questions

Chinese researcher claims birth of first gene

explore

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Pharma budget tightening trickles down to Doximity

Novo acquires Inversago for up to $1 billion

Pharma budget tightening trickles down to Doximity

Mirador, a new biotech startup, launches with $400 million

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

hotspot

explore

knowledge

entertainment